Literature DB >> 16957460

How safe is aggressive statin therapy?

Robert M Guthrie1.   

Abstract

The most recent guidelines of the National Cholesterol Education Program recommend more aggressive low-density lipoprotein cholesterol goals: <100 mg/dL for patients at moderate or high risk of cardiovascular disease, and <70 mg/dL for patients at very high risk. These lower goals are more likely to be achieved using the more powerful statins--atorvastatin, rosuvastatin, and simvastatin. Although statins are widely used, extensively studied, and known to have an excellent safety profile, the perception of many health care providers and patients is that safety concerns about the more efficacious statins, especially at high doses, limit their use. However, clinical data consistently support the view that adverse events are uncommon even when intensive therapy is used to reach aggressive low-density lipoprotein cholesterol goals. Overall, the more potent statins have similar safety profiles. The benefits of aggressive statin treatment in reducing the risk of cardiovascular events appear to far outweigh any potential risks of adverse events.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957460     DOI: 10.1111/j.0889-7204.2006.05616.x

Source DB:  PubMed          Journal:  Prog Cardiovasc Nurs        ISSN: 0889-7204


  4 in total

1.  Should we treat all primary prevention patients with statins?

Authors:  Robert Guthrie
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

2.  Collagen with simvastatin promotes cell metabolism in osteoblast-like SaOS-2 cells.

Authors:  Thanga Kumaran Suthanthiran; Sugumari Elavarasu; Devisree Naveen; Umamaheswari Nagarathinam; K V Arun; N Srinivasan
Journal:  J Pharm Bioallied Sci       Date:  2012-08

3.  Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis.

Authors:  Peter P Toth; Victoria Zarotsky; Jane M Sullivan; Dave Laitinen
Journal:  Cardiovasc Diabetol       Date:  2009-05-18       Impact factor: 9.951

4.  Safety of statins.

Authors:  Debasish Maji; Shehla Shaikh; Dharmesh Solanki; Kumar Gaurav
Journal:  Indian J Endocrinol Metab       Date:  2013-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.